| Literature DB >> 2859879 |
Abstract
The clinical efficacy of alprazolam has been evaluated in both anxiety states and depressive disorders. In anxiety neurosis, studies have been conducted vs placebo and/or other benzodiazepine tranquilizers. Reports, to date, with regard to panic/phobia disorders have been limited to open-label studies and a single report from a placebo-controlled study. In depression, both open-label and double-blind studies (vs tricyclic antidepressants) have been published.Entities:
Mesh:
Substances:
Year: 1985 PMID: 2859879 PMCID: PMC1463502 DOI: 10.1111/j.1365-2125.1985.tb02743.x
Source DB: PubMed Journal: Br J Clin Pharmacol ISSN: 0306-5251 Impact factor: 4.335